Abstract
Vacuolar-type ATPases are multicomponent proton pumps involved in the acidification of single membrane intracellular compartments such as endosomes and lysosomes. They couple the hydrolysis of ATP to the translocation of one to two protons across the membrane. Acidification of the lumen of single membrane organelles is a necessary factor for the correct traffic of membranes and cargo to and from the different internal compartments of a cell. Also, V-ATPases are involved in regulation of pH at the cytosol and, possibly, extracellular milieu. The inhibition of V-ATPases has been shown to induce apoptosis and cell cycle arrest in tumour cells and, therefore, chemicals that behave as inhibitors of this kind of proton pumps have been proposed as putative treatment agents against cancer and many have been patented as such. The compounds filed in patents fall into five major types: plecomacrolides, benzolactone enamides, archazolids, chondropsins and indoles. All these have proved to be apoptosis inducers in cell culture and many to be able to reduce xenograft tumor growth in murine models. The present review will summarize their general structure, origin and mechanisms of action and put them in relation to the patents registered so far for the treatment of cancer.
Keywords: V-ATPase, bafilomycin, chondropsin, concanamycin, salicylihalamide
Recent Patents on Anti-Cancer Drug Discovery
Title: Intraorganellar Acidification by V-ATPases: A Target in Cell Proliferation and Cancer Therapy
Volume: 5 Issue: 2
Author(s): Agustin Hernandez, Gloria Serrano, Rosana Herrera-Palau, Jose R. Perez-Castineira and Aurelio Serrano
Affiliation:
Keywords: V-ATPase, bafilomycin, chondropsin, concanamycin, salicylihalamide
Abstract: Vacuolar-type ATPases are multicomponent proton pumps involved in the acidification of single membrane intracellular compartments such as endosomes and lysosomes. They couple the hydrolysis of ATP to the translocation of one to two protons across the membrane. Acidification of the lumen of single membrane organelles is a necessary factor for the correct traffic of membranes and cargo to and from the different internal compartments of a cell. Also, V-ATPases are involved in regulation of pH at the cytosol and, possibly, extracellular milieu. The inhibition of V-ATPases has been shown to induce apoptosis and cell cycle arrest in tumour cells and, therefore, chemicals that behave as inhibitors of this kind of proton pumps have been proposed as putative treatment agents against cancer and many have been patented as such. The compounds filed in patents fall into five major types: plecomacrolides, benzolactone enamides, archazolids, chondropsins and indoles. All these have proved to be apoptosis inducers in cell culture and many to be able to reduce xenograft tumor growth in murine models. The present review will summarize their general structure, origin and mechanisms of action and put them in relation to the patents registered so far for the treatment of cancer.
Export Options
About this article
Cite this article as:
Hernandez Agustin, Serrano Gloria, Herrera-Palau Rosana, Perez-Castineira R. Jose and Serrano Aurelio, Intraorganellar Acidification by V-ATPases: A Target in Cell Proliferation and Cancer Therapy, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (2) . https://dx.doi.org/10.2174/157489210790936216
DOI https://dx.doi.org/10.2174/157489210790936216 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)
Current Cancer Drug Targets Global Genomic Approaches to the Study of Human Gene Function
Current Genomics Synthesis and Properties of N1-(indan-5-yl)amidrazones Incorporating Piperazines and Related Congeners
Letters in Organic Chemistry Nigella sativa and Cancer: A Review Focusing on Breast Cancer, Inhibition of Metastasis and Enhancement of Natural Killer Cell Cytotoxicity
Current Pharmaceutical Biotechnology Src as a Therapeutic Target in Breast Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of Anti-Infective Drugs in Rheumatology
Anti-Infective Agents in Medicinal Chemistry A Novel Triazole Derivative Drug Presenting In Vitro and In Vivo Anticancer Properties
Current Topics in Medicinal Chemistry Fertility Preservation and Treatment for Cervical Cancer
Current Women`s Health Reviews Role of Polymorphisms of FAM13A, PHLDB1, and CYP24A1 in Breast Cancer Risk
Current Molecular Medicine Xanthan Gum and Its Derivatives as a Potential Bio-polymeric Carrier for Drug Delivery System
Current Drug Delivery Degludec: A Novel Basal Insulin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeting Tumor Angiogenesis in Gastrointestinal Malignancies
Current Angiogenesis (Discontinued) Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Digital Mammograms with Image Enhancement Techniques for Breast Cancer Detection: A Systematic Review
Current Medical Imaging Applications of Nanomaterials for Cancer Treatment: Recent Patents Review
Recent Patents on Nanomedicine miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth
MicroRNA Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Synthesis and Characterization of Folic Acid Conjugated Gemcitabine Tethered Silver Nanoparticles (FA-GEM-AgNPs) for Targeted Delivery
Current Pharmaceutical Design